The strong beat and raised guidance signal accelerating bioprocessing demand and market share gains. The BioLife acquisition adds a high-margin, recurring-revenue cell therapy platform. Watch for integration updates and margin trajectory in coming quarters; the stock may re-rate higher if organic momentum continues.
Price Chart
Executive Summary
Repligen reported Q2 2026 revenue of $204M (+12% YoY) and adjusted EPS of $0.54, beating consensus by 20.4%. The company raised full-year 2026 guidance for organic revenue growth to 10.5%-13.5% and adjusted EPS to $2.03-$2.09, while also announcing a definitive agreement to acquire BioLife Solutions, a strategic move into cell therapy consumables.
Key Financial Metrics
Key Facts
- Q2 2026 revenue $204M, +12% reported and +13% organic YoY
- Adjusted EPS $0.54 vs consensus $0.45 (beat by 20.4%)
- GAAP EPS $0.09 vs $0.26 YoY due to acquisition/amortization costs
- Raised FY26 guidance: organic growth 10.5%-13.5%, adjusted EPS $2.03-$2.09
- Announced definitive agreement to acquire BioLife Solutions (cell therapy consumables)
- Adjusted operating margin expanded to 16.7% from 12.0% YoY
- Cash and marketable securities $810M at June 30, 2026
Financial Impact
Revenue growth of 12% YoY and adjusted EPS growth of 46% YoY; full-year guidance raised by ~$0.10 at midpoint
Risk Factors
- Integration risk from BioLife acquisition; potential dilution from stock issuance
- GAAP EPS depressed by amortization and deal costs may cause confusion
- Macro headwinds in biotech funding could slow customer orders
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-318853 |
| Document: 0001193125-26-318853-index.html | 0001193125-26-318853 |
| Document: 0001193125-26-318853.txt | 0001193125-26-318853 |
| 8-K Data (Synthetic) | 0001193125-26-318853 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | S-4 | $181.69 $184.53 | ▲ +1.56% | ▲ +0.59% | $183.85 (+1.19%) |
Jul 28, 2026 9w ago | 8-K | $145.34 $181.69 | ▲ +25.01% | ▲ +21.63% | $183.85 (+26.49%) |
Jul 22, 2026 10w ago | 425 / 8-K | $140.09 $176.36 | ▲ +25.89% | ▲ +22.99% | $183.85 (+31.23%) |
Jul 22, 2026 10w ago | Press Release | $140.09 $176.36 | ▲ +25.89% | ▲ +22.99% | $183.85 (+31.23%) |
Jun 11, 2026 16w ago | Institutional Cluster | $130.59 $144.24 | ▲ +10.45% | ▲ +8.67% | $183.85 (+40.78%) |
May 5, 2026 21w ago | 8-K | $125.61 $121.13 | ▼ −3.57% | ▼ −8.52% | $183.85 (+46.36%) |
May 5, 2026 21w ago | Press Release | $125.61 $121.13 | ▼ −3.57% | ▼ −8.52% | $183.85 (+46.36%) |
Apr 22, 2026 23w ago | Press Release | $124.40 $108.52 | ▼ −12.77% | ▼ −15.93% | $183.85 (+47.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access